Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Business Update

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022


Regulatory News:

Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2022.

"During the first half of 2022, we remained focused on advancing the development of our therapeutic programs. As announced in early 2022, both our SACT-1 program (targeting neuroblastoma) and ALS-4 program (targeting MRSA), has announced the completion and positive Phase I clinical trial results. Our RPIDD program (liquid biopsy based approach to infectious disease rapid molecular diagnostics) are also progressing well into its clinical validation studies. We are excited to work towards the commencement of the relevant phase II clinical trials for our ALS-4 and SACT-1 programs and the continuation of the clinical validation of our RPIDD program. Finally, we are also pleased to have announced the commercialization of our NativusWell® nutraceutical product, a novel supplement targeting woman's health including menopausal symptoms, commencing in Hong Kong initially and to be followed into the European and US markets in due course," said Mr. Darren Lui, Chief Executive Officer and Executive Director of Aptorum Group Limited.

Clinical Pipeline Update and Upcoming Milestones

In January 2022, Aptorum Group announced the completion of the Phase I clinical trial for ALS-4,, a small molecule drug targeting methicillin-resistant staphylococcus aureus related infections. The Phase I clinical trial of ALS-4 was a randomized, double-blinded, placebo-controlled, single and multiple ascending dose study designed to evaluate safety, tolerability, and pharmacokinetics or orally administered ALS-4 in healthy male and female adult volunteers. Currently, the Company is preparing the relevant submission to the US FDA to initiate a Phase 2 clinical trials for skin and soft tissue infections and/or bacteraemia. The study treatments were well tolerated and no serious adverse events were observed and no relevant clinical changes in respect of vital signs and clinical laboratory test results.

In May 2022, Aptorum Group announced the finalized data from the Phase I clinical trial of SACT-1, a repurposed small molecule drug targeting Neuroblastoma and potentially other cancer types. The Phase I clinical trial of SACT-1 was an open-label, randomized, 3-period, 3-sequence, single-dose crossover bioavailability and food effect study of SACT-1 (oral suspension) in healthy adult volunteers. The study treatments were well tolerated and no subjects were discontinued from study participation because of adverse events. No serious adverse events were reported during the study. SACT-1 also received Orphan Drug Designation from the US FDA.

In September 2022, Aptorum Group announced further results and updates from its RPIDD's analytical and clinical validations in patient samples. It was further announced the company has taken steps to initiate the set up of a clinical laboratory in the state of California, which is targeted to require relevant CLIA certification.

In September 2022, Aptorum Group announced the commencement of sale of its NativusWell® nutraceutical product targeting woman's health and the launch of it's initial sales launch in Hong Kong, to be followed in Europe and United States.

Corporate Highlights

In May 2022, Mr. Darren Lui has been appointed as the Chief Executive Officer. Mr. Lui was previously the Aptorum Group Limited's President, successfully brought two small molecule drugs (ALS-4 and SACT-1) from discovery to their respective completion of two phase I clinical trials and currently in preparation for their next phase of clinical trials in human patients, as well as conducting ongoing clinical validations of the Company's RPIDD program, a liquid biopsy based molecular diagnostics for infectious diseases.

In July 2022, Mr. Martin Siu has been appointed as the Head of Finance. Mr. Siu has over 19 years' experience in the field of audit and regulatory consultancy and has supported a number of listed companies over the years.

Financial Results for the Six Months Ended June 30, 2022

Aptorum Group reported a net loss of $2.7 million for the six months ended June 30, 2022 compared to $17.1 million for the same period in 2021. The decrease in net loss in the current period was driven by an decrease of loss on investments in marketable securities, net of $7.5 million, and there was a gain on non-marketable investment of $5.6 million in 2022 while there was no such gain in the same period in 2021.

Research and development expenses were $4.5 million for the six months ended June 30, 2022 compared to $5.5 million for the same period in 2021. The decrease in research and development expenses was mainly due to the decrease in services provided by contracted research organizations as we are in a planning process for Phase 2 of our lead projects which does not require many services from contracted research organizations.

General and administrative fees were $2.4 million for the six months ended June 30, 2022 compared to $2.6 million for the same period in 2021. The decrease in general and administrative fees was primary due to the decrease in number of employees.

Legal and professional fees were $1.4 million for the six months ended June 30, 2022 compared to $1.2 million for the same period in 2021. The increase in legal and professional fees was mainly due to more share based compensation awards was granted for consultancy services when compared to the same period in 2021.

As of June 30, 2022, cash and restricted cash totalled approximately $7.2 million and total equity was approximately $15.6 million.

Aptorum Group expects that its existing cash and restricted cash together with undrawn line of credit facility from related parties, will enable it to fund its operating and capital expenditure requirements for at least the next 12 months.

APTORUM GROUP LIMITED

CONDENSED CONSOLIDATED BALANCE SHEETS

(Stated in U.S. Dollars)

 

 

 

June 30,
2022

 

 

December 31,
2021

 

 

 

(Unaudited)

 

 

 

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash

 

$

4,065,788

 

 

$

8,131,217

 

Restricted cash

 

 

3,130,270

 

 

 

130,270

 

Accounts receivable

 

 

71,814

 

 

 

78,722

 

Inventories

 

 

29,704

 

 

 

35,775

 

Marketable securities, at fair value

 

 

153,905

 

 

 

236,615

 

Amounts due from related parties

 

 

141,457

 

 

 

47,754

 

Due from brokers

 

 

76,330

 

 

 

76,380

 

Loan receivable from a related party

 

 

657,404

 

 

 

3,358,089

 

Other receivables and prepayments

 

 

997,900

 

 

 

593,478

 

Total current assets

 

 

9,324,572

 

 

 

12,688,300

 

Property, plant and equipment, net

 

 

3,331,498

 

 

 

3,731,116

 

Operating lease right-of-use assets

 

 

495,415

 

 

 

154,439

 

Long-term investments

 

 

9,744,985

 

 

 

4,156,907

 

Intangible assets, net

 

 

826,184

 

 

 

880,256

 

Long-term deposits

 

 

295,891

 

 

 

296,225

 

Total Assets

 

$

24,018,545

 

 

$

21,907,243

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Amounts due to related parties

 

$

46

 

 

$

11,389

 

Accounts payable and accrued expenses

 

 

4,843,862

 

 

 

4,172,565

 

Finance lease liabilities, current

 

 

22,106

 

 

 

47,923

 

Operating lease liabilities, current

 

 

339,649

 

 

 

145,391

 

Loan payables

 

 

3,000,000

 

 

 

-

 

Total current liabilities

 

 

8,205,663

 

 

 

4,377,268

 

Operating lease liabilities, non-current

 

 

163,906

 

 

 

23,853

 

Total Liabilities

 

$

8,369,569

 

 

$

4,401,121

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

 

 

 

 

Class A Ordinary Shares ($1.00 par value; 60,000,000 shares authorized, 13,265,503 and 13,202,408 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively)

 

$

13,265,503

 

 

$

13,202,408

 

Class B Ordinary Shares ($1.00 par value; 40,000,000 shares authorized, 22,437,754 shares issued and outstanding as of June 30, 2022 and December 31, 2021)

 

 

22,437,754

 

 

 

22,437,754

 

Additional paid-in capital

 

 

44,336,942

 

 

 

43,506,717

 

Accumulated other comprehensive income (deficit)

 

 

29,327

 

 

 

(2,019

)

Accumulated deficit

 

 

(57,422,767

)

 

 

(55,537,515

)

Total equity attributable to the shareholders of Aptorum Group Limited

 

 

22,646,759

 

 

 

23,607,345

 

Non-controlling interests

 

 

(6,997,783

)

 

 

(6,101,223

)

Total equity

 

 

15,648,976

 

 

 

17,506,122

 

Total Liabilities and Equity

 

$

24,018,545

 

 

$

21,907,243

 

APTORUM GROUP LIMITED

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(Stated in U.S. Dollars)

 

 

 

For the six months ended
June 30,

 

 

 

2022

 

 

2021

 

 

 

(Unaudited)

 

 

(Unaudited)

 

Revenue

 

 

 

 

 

 

Healthcare services income

 

$

527,462

 

 

$

637,784

 

Operating expenses

 

 

 

 

 

 

 

 

Costs of healthcare services

 

 

(529,991

)

 

 

(629,987

)

Research and development expenses

 

 

(4,509,303

)

 

 

(5,508,356

)

General and administrative fees

 

 

(2,400,418

)

 

 

(2,564,117

)

Legal and professional fees

 

 

(1,356,164

)

 

 

(1,240,512

)

Other operating expenses

 

 

(183,104

)

 

 

(189,125

)

Total operating expenses

 

 

(8,978,980

)

 

 

(10,132,097

)

 

 

 

 

 

 

 

 

 

Other income (loss)

 

 

 

 

 

 

 

 

Loss on investments in marketable securities, net

 

 

(82,710

)

 

 

(7,565,273

)

Gain on non-marketable investment, net

 

 

5,588,078

 

 

 

-

 

Loss on investments in derivatives, net

 

 

-

 

 

 

(4,289

)

Gain on use of digital currencies

 

 

-

 

 

 

4,918

 

Interest income (expense), net

 

 

149,734

 

 

 

(126,102

)

Sundry income

 

 

66,628

 

 

 

82,652

 

Total other income (loss), net

 

 

5,721,730

 

 

 

(7,608,094

)

 

 

 

 

 

 

 

 

 

Net loss

 

$

(2,729,788

)

 

$

(17,102,407

)

Less: net loss attributable to non-controlling interests

 

 

(844,536

)

 

 

(1,020,983

)

 

 

 

 

 

 

 

 

 

Net loss attributable to Aptorum Group Limited

 

$

(1,885,252

)

 

$

(16,081,424

)

 

 

 

 

 

 

 

 

 

Net loss per share ? basic and diluted

 

$

(0.05

)

 

$

(0.47

)

Weighted-average shares outstanding ? basic and diluted

 

 

35,682,652

 

 

 

34,280,137

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(2,729,788

)

 

$

(17,102,407

)

Other comprehensive income (loss)

 

 

 

 

 

 

 

 

Exchange differences on translation of foreign operations

 

 

31,346

 

 

 

(25,029

)

Other comprehensive income (loss)

 

 

31,346

 

 

 

(25,029

)

Comprehensive loss

 

 

(2,698,442

)

 

 

(17,127,436

)

Less: comprehensive loss attributable to non-controlling interests

 

 

(844,536

)

 

 

(1,020,983

)

Comprehensive loss attributable to the shareholders of Aptorum Group Limited

 

 

(1,853,906

)

 

 

(16,106,453

)

About Aptorum Group

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications), autoimmune and infectious diseases. Aptorum has completed two phase I clinical trials for its ALS-4 (MRSA) and orphan drug designated SACT-1 (Neuroblastoma) small molecule drugs and commercializing its NLS-2 NativusWell® nutraceutical (menopause). The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development and ongoing clinical validation of its novel molecular-based rapid pathogen identification and detection diagnostics technology with Singapore's Agency for Science, Technology and Research.

For more information about the Company, please visit www.aptorumgroup.com.

Disclaimer and Forward-Looking Statements

This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations.

These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company's anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group's Form 20-F and other filings that Aptorum Group may make with the SEC in the future, as well as the prospectus that received the French Autorité des Marchés Financiers visa n°20-352 on 16 July 2020. As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein.

Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

This announcement is not a prospectus within the meaning of the Regulation (EU) n°2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n°2019/980 of 14 March 2019 and n°2019/979 of 14 March 2019.

This press release is provided "as is" without any representation or warranty of any kind.


These press releases may also interest you

at 00:41
Max Stock Limited (the "Company") today reported financial results for third quarter ended September 30, 2022. Third Quarter 2022 Summary Revenue increased 14.8% to ILS 293.5 million.Gross profit increased 19.4% to ILS 117.7 million.Comparable...

at 00:00
The Covid crisis has led many governments worldwide to reorganize their healthcare systems in order to reinforce their services to their citizens. However, these programs may be subject to ID fraud, leading healthcare departments to look for a...

at 00:00
Yidu Tech Inc. ("Yidu Tech" or "the Company", together with its subsidiaries and consolidated affiliated entities, "the Group", HKEx: 2158), a leading corporate in China's healthcare intelligence industry, announced the interim results for the six...

27 nov 2022
DWF Labs, the multi-stage Web3 investment firm, has recently launched operations in Korea, and has now doubled down its commitment to support the Web3 ecosystem in the region. This partnership comes with a 6-digit investment in the ever-expanding MBX...

27 nov 2022
Trip.com Group and the National Company Kazakh Tourism signed a new cooperation agreement at the World Travel Market exhibition in London earlier this month. Following several successful events held in Kazakhstan, the National Company "Kazakh...

27 nov 2022
Finastra today announced a new Center of Excellence (COE) at Malaysia's MRANTI Technology Park in Bukit Jalil, Kuala Lumpur. MRANTI Park is a hub for technology innovation, commercial adoption, and scientific excellence. It is an ideal location...



News published on 30 september 2022 at 19:45 and distributed by: